                         SEQUENCE LISTING

<110>  The General Hospital Corporation
 
<120>  PARATHYROID HORMONE POLYPEPTIDE CONJUGATES AND METHODS OF THEIR 
       USE

<130>  51313-002WO2

<150>  US 62/644,316
<151>  2018-03-16

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  34
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  1

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 
1               5                   10                  15      


Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
            20                  25                  30          


Asn Phe 
        


<210>  2
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  2

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His 
            20                  25                  30          


Thr Ala Glu Ile 
        35      


<210>  3
<211>  84
<212>  PRT
<213>  Homo sapiens

<400>  3

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 
1               5                   10                  15      


Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
            20                  25                  30          


Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser 
        35                  40                  45              


Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu 
    50                  55                  60                  


Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys 
65                  70                  75                  80  


Ala Lys Ser Gln 
                


<210>  4
<211>  34
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  4

Trp Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 
1               5                   10                  15      


Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
            20                  25                  30          


Asn Phe 
        


<210>  5
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Nle

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is dTrp

<400>  5

Leu Xaa His Gln Leu Xaa Lys Trp Ile Gln Asp Ala Arg Arg Arg Ala 
1               5                   10                  15      


Trp Leu His Lys Leu Ile Ala Glu Ile His Thr Ala Glu Ile 
            20                  25                  30  


<210>  6
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is Aib

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Aib

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is Har

<400>  6

Xaa Val Xaa Glu Ile Gln Leu Met His Gln Xaa Ala Lys Trp 
1               5                   10                  


<210>  7
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Nle

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is dTrp

<400>  7

Leu Xaa His Gln Leu Xaa Lys Trp Ile Gln Asp Ala Arg Arg Arg Ala 
1               5                   10                  15      


Trp Leu Leu Lys Leu Ile Ala Glu Ile His Thr Ala Glu Ile 
            20                  25                  30  


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is epsilon-palmitoyllysine

<400>  8

Glu Tyr Glu Xaa Glu Tyr Glu 
1               5           


